Treatment update in multiple sclerosis

Current Allergy and Asthma Reports

Volumn 12, Issue 3, 2012, Pages 246-254

  Morris, Katrina ^a   Yiannikas, Con ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Alemtuzumab; Algorithm; Cladribine; Dimethyl fumarate; Fingolimod; Glatiramer acetate; Interferon beta; Mitoxantrone; Multiple sclerosis; Natalizumab; Rituximab; Treatment

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE;

ABDOMINAL PAIN; ADD ON THERAPY; ARTICLE; ATRIOVENTRICULAR BLOCK; BASAL CELL CARCINOMA; BRADYCARDIA; BRONCHITIS; CHICKENPOX; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY INTERVENTION; ERYTHEMA; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; HAIR DISEASE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HERPES SIMPLEX ENCEPHALITIS; HERPES VIRUS INFECTION; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; INFERTILITY; INJECTION SITE REACTION; LEIOMYOMA; LEUKEMIA; LIPOATROPHY; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; MELANOMA; MULTIPLE SCLEROSIS; NAUSEA; OVARY CARCINOMA; PANCREAS CANCER; PREGNANCY OUTCOME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RETINA MACULA EDEMA; SIDE EFFECT; SKIN CANCER; STENT; THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; UTERINE CERVIX CANCER;

AGE DISTRIBUTION; COST OF ILLNESS; DISEASE PROGRESSION; HUMANS; LIFE EXPECTANCY; MULTIPLE SCLEROSIS; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84861233384     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-012-0256-5     Document Type: Article

References (49)

1. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366(4):339-47.
2. Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental? J Neurol Neurosurg Psychiatry. 1990;53(10):903-5. (Pubitemid 20351058)
3. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727-39.
4. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-55.
5. Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 2010;33(3):140-52.
6. Howell ORN, Nicholas R, Carassiti D, Roncaroli F, Magliozzi R, Aloisi F, et al. Oral Presentation 105 in Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19-22, 2011. Amsterdam, The Netherlands. Mult Scler. 2011;17(10 Suppl):S9-524.
7. Kieseier BC, Stuve O. A critical appraisal of treatment decisions in multiple sclerosis-old versus new. Nat Rev Neurol. 2011;7(5): 255-62.
8. Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66 (5):678-84. (Pubitemid 43739821)
9. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503- 11.
10. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268): 1576-82. (Pubitemid 32488815)
11. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364(9444):1489-96. (Pubitemid 39410414)
12. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987-97.
13. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):282-7.
14. Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008;71(24 Suppl 3): S8-13.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33 (11):1444-52. (Pubitemid 14237132)
16. Pozzilli C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci. 2008;29 Suppl 2:S211-3.
17. Hartung HP, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol. 2011;10(4):293-5.
18. Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis Markers. 2006;22(4):187-96. (Pubitemid 44763272)
19. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-14.
20. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-97.
21. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):899-910.
22. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8 (3):254-60.
23. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-23.
24. Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9): 806-12.
25. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745-58.
26. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.
27. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
28. Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2010;10(5):381-8.
29. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15.
30. Lindsey J, Haden-Pinneri K, Memon N, Buja L. Sudden unexpected death on fingolimod. Mult Scler. 2012 Feb 2.
31. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801.
32. Boggild M. Immunosuppression followed by immunomodulation. J Neurol Sci. 2009;277 Suppl 1:S50-4.
33. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011;77(21): 1887-95.
34. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61(10):1332-8. (Pubitemid 37463366)
35. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-88. (Pubitemid 351240747)
36. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10(11):1026-34.
37. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-26.
38. Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329-37.
39. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303.
40. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012 Feb 7.
41. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-72.
42. Gold RKL, Bar-Or A, Arnold D, Giovannoni G, Selmaj K, Yang M, et al. Oral presentation 95 in Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19-22, 2011. Amsterdam, The Netherlands. Mult Scler. 2011;17(10 Suppl):S9-524.
43. MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients withmultiple sclerosis. J Neurol. 2011;258(3):449-56.
44. Selmaj KGR, Kappos L, Bar-Or A, Arnold DL, Giovannoni G, Sweetser M, NovasM, Raghupathi K, Sheikh SI, Dawson KT. Poster 994 Safety and Tolerability of BG-12 in the Phase 3 DEFINE Trial in Patients with Relapsing-Remitting Multiple Sclerosis. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis October 19-22, 2011 [serial on the Internet]. http://www.posters2view.com/ECTRIMS2011/numindex.php accessed 28 Feb 2012.
45. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(4):392-9.
46. D'Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011;10 (7):657-66.
47. Reekers JA, Lee MJ, Belli AM, Barkhof F. Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol. 2011;34(1):1-2.
48. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010;9(12):1182-99.
49. Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neurother. 2011;11(3):351-62.